About the Fund

We seek visionary founders and innovative startups dedicated to tackling global longevity challenges.


The name of this fund is inspired by Methuselah who lived to be 969 years in the Bible.

969 is dedicated to advancing human longevity and well-being. We aim to seize the substantial market opportunity in the longevity sector, capitalizing on the convergence of cutting-edge technology, demographic shifts, and heightened consumer interest in healthy aging. With support from visionary investors and innovative startups; and by harnessing the expertise of industry leader Dave Asprey and collaborating with the Percival and Brock Pierce’s family office; 969 is positioned to make impactful investments that not only deliver attractive financial returns but also contribute to the advancement of human longevity.

Our goal is to collaborate with experts and innovators, leveraging their expertise from top research institutions and biotechnology companies, to develop ethical, effective, and accessible solutions for extended healthy lifespans. The time is now to invest in longevity, and we are excited to be at the forefront of this endeavor.


Human longevity has evolved remarkably. Early humans faced short life expectancies due to hazards and predation. Agriculture marked progress, enabling stable food sources and population growth. Some ancient individuals lived into their 60s and 70s. The Middle Ages brought challenges like famine and disease, reducing life expectancies. Science and medicine advances during the Renaissance and Enlightenment improved longevity. The Industrial Revolution enhanced living conditions, nutrition, and healthcare access. The 20th century saw significant life expectancy gains due to medical progress and healthier lifestyles. Today, global life expectancy rises, with disparities tied to socioeconomic factors and healthcare access. Ongoing research offers hope for extending lifespan.

Our Opportunity

  • The global anti-aging market is projected to reach $66.2 billion by 2025, with a CAGR of 5.7% (Market Data Forecast). 
  • The global longevity and anti-senescence therapy market was valued at $329.8 million in 2019 and is anticipated to grow at a CAGR of 8.6% from 2020 to 2027 (Gitnux Market Data).
  • Venture capital funds dedicated to aging research and longevity startups raised over $850 million. (Business Insider
  • The broader longevity market spans multiple sectors, including biotechnology, pharmaceuticals, digital health, and wellness, with growth potential in each segment.

We seek visionary founders and innovative startups dedicated to tackling global longevity challenges.